Bristol-Myers Squibb Co (BMY)
43.99
+0.09
(+0.21%)
USD |
NYSE |
May 07, 11:44
Bristol-Myers Squibb Enterprise Value: 135.05B for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 135.05B |
| May 03, 2024 | 135.24B |
| May 02, 2024 | 134.65B |
| May 01, 2024 | 135.68B |
| April 30, 2024 | 135.14B |
| April 29, 2024 | 136.55B |
| April 26, 2024 | 136.98B |
| April 25, 2024 | 136.68B |
| April 24, 2024 | 145.11B |
| April 23, 2024 | 145.37B |
| April 22, 2024 | 145.68B |
| April 19, 2024 | 145.25B |
| April 18, 2024 | 143.97B |
| April 17, 2024 | 143.04B |
| April 16, 2024 | 143.89B |
| April 15, 2024 | 144.39B |
| April 12, 2024 | 143.93B |
| April 11, 2024 | 145.63B |
| April 10, 2024 | 148.00B |
| April 09, 2024 | 150.66B |
| April 08, 2024 | 149.64B |
| April 05, 2024 | 150.09B |
| April 04, 2024 | 150.25B |
| April 03, 2024 | 151.83B |
| April 02, 2024 | 152.97B |
| Date | Value |
|---|---|
| April 01, 2024 | 153.48B |
| March 31, 2024 | 155.99B |
| March 28, 2024 | 137.46B |
| March 27, 2024 | 135.47B |
| March 26, 2024 | 134.05B |
| March 25, 2024 | 133.45B |
| March 22, 2024 | 132.80B |
| March 21, 2024 | 132.11B |
| March 20, 2024 | 132.70B |
| March 19, 2024 | 132.53B |
| March 18, 2024 | 132.11B |
| March 15, 2024 | 133.63B |
| March 14, 2024 | 133.93B |
| March 13, 2024 | 134.02B |
| March 12, 2024 | 137.55B |
| March 11, 2024 | 137.47B |
| March 08, 2024 | 136.32B |
| March 07, 2024 | 135.29B |
| March 06, 2024 | 135.49B |
| March 05, 2024 | 132.34B |
| March 04, 2024 | 130.52B |
| March 01, 2024 | 130.46B |
| February 29, 2024 | 130.17B |
| February 28, 2024 | 130.52B |
| February 27, 2024 | 129.69B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
65.68B
Minimum
Jul 22 2019
202.63B
Maximum
Dec 02 2022
156.49B
Average
165.66B
Median
Enterprise Value Benchmarks
| Amgen Inc | 215.00B |
| Gilead Sciences Inc | 77.02B |
| Johnson & Johnson | 365.00B |
| Karuna Therapeutics Inc (DELISTED) | 11.34B |
| 2seventy bio Inc | 37.00M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.91B |
| Revenue (Quarterly) | 11.86B |
| Total Expenses (Quarterly) | 10.35B |
| EPS Diluted (Quarterly) | -5.89 |
| Gross Profit Margin (Quarterly) | 75.29% |
| Profit Margin (Quarterly) | -100.4% |
| Earnings Yield | -7.05% |
| Operating Earnings Yield | 8.05% |
| Normalized Earnings Yield | 1.756 |